BioToxTech Co

BioToxTech Co Deferred Tax Liabilities

The Deferred Tax Liabilities of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 592.00 M KRW. In the previous year, Deferred Tax Liabilities was 1.47 B KRW — a change of -59.84% (lower).

Deferred Tax Liabilities

592.00 MKRW

YoY

-59.84%

Last updated:

Deferred Tax Liabilities of BioToxTech Co is 2018 592.00 M KRW. Deferred Tax Liabilities of BioToxTech Co was 2017 1.47 B KRW. It decreases by -59.84% lower compared to the previous year.

The BioToxTech Co Deferred Tax Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Deferred Tax Liabilities
Date
Deferred Tax Liabilities
Jan 1, 2017
1.47 B KRW
Jan 1, 2018
592.00 M KRW
The BioToxTech Co Deferred Tax Liabilities history
YEARDeferred Tax LiabilitiesYoY
592.00 MKRW-59.84%
1.47 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Deferred Tax Liabilities of BioToxTech Co is 592.00 M KRW in 2018.

Deferred Tax Liabilities of BioToxTech Co changed from 1.47 B KRW to 592.00 M KRW, representing a -59.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Deferred Tax Liabilities BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

Deferred tax liabilities arise from temporary differences between accounting and tax treatments. They represent taxes owed in the future on income already recognized.

Deferred Tax Liabilities's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Deferred Tax Liabilities's BioToxTech Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — BioToxTech Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — BioToxTech Co